Transforming Growth Factor β₁ Oppositely Regulates the Hypertrophic and Contractile Response to β-Adrenergic Stimulation in the Heart

Michael Huntgeburth¹*, Klaus Tiemann²*, Robert Shahverdyan¹, Klaus-Dieter Schlüter³, Rolf Schreckenberg³, Marie-Luise Gross⁴, Sonja Mödersheim⁴, Evren Caglayan¹,⁵, Jochen Müller-Ehmsen¹, Alexander Ghanem⁶, Marius Vantler¹,⁵, Wolfram H. Zimmermann⁷, Michael Böhm⁸, Stephan Rosenkranz¹,⁵*

¹ Klinik für Innere Medizin, Herzzentrum der Universität zu Köln, Cologne, Germany, ² Abteilung für Kardiologie und Angiologie, Universitätsklinikum Münster, Münster, Germany, ³ Institut für Physiologie, Justus-Liebig-Universität Gießen, Gießen, Germany, ⁴ Institut für Pathologie, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany, ⁵ Center for Molecular Medicine Cologne (CMMC), Universität zu Köln, Cologne, Germany, ⁶ Medizinische Klinik und Poliklinik II, Universitätsklinikum Bonn, Bonn, Germany, ⁷ Abteilung für Pharmakologie, Georg August Universität Göttingen, Göttingen, Germany, ⁸ Klinik für Innere Medizin III, Universität des Saarlandes, Homburg/Saar, Germany

Abstract

**Background:** Neuroendocrine activation and local mediators such as transforming growth factor-β₁ (TGF-β₁) contribute to the pathobiology of cardiac hypertrophy and failure, but the underlying mechanisms are incompletely understood. We aimed to characterize the functional network involving TGF-β₁, the renin-angiotensin system, and the β-adrenergic system in the heart.

**Methods:** Transgenic mice overexpressing TGF-β₁ (TGF-β₁-Tg) were treated with a β-blocker, an AT₁-receptor antagonist, or a TGF-β₁-antagonist (sTGFβRII-Fc), were morphologically characterized. Contractile function was assessed by dobutamine stress echocardiography in vivo and isolated myocytes in vitro. Functional alterations were related to regulators of cardiac energy metabolism.

**Results:** Compared to wild-type controls, TGF-β₁-Tg mice displayed an increased heart-to-body-weight ratio involving both fibrosis and myocyte hypertrophy. TGF-β₁ overexpression increased the hypertrophic responsiveness to β-adrenergic stimulation. In contrast, the inotropic response to β-adrenergic stimulation was diminished in TGF-β₁-Tg mice, albeit unchanged basal contractility. Treatment with sTGFβRII-Fc completely prevented the cardiac phenotype in transgenic mice. Chronic β-blocker treatment also prevented hypertrophy and ANF induction by isoprenaline, and restored the inotropic response to β-adrenergic stimulation without affecting TGF-β₁ levels, whereas AT₁-receptor blockade had no effect. The impaired contractile reserve in TGF-β₁-Tg mice was accompanied by an upregulation of mitochondrial uncoupling proteins (UCPs) which was reversed by β-adrenoceptor blockade. UCP-inhibition restored the contractile response to β-adrenoceptor stimulation in vitro and in vivo. Finally, cardiac TGF-β₁ and UCP expression were elevated in heart failure in humans, and UCP – but not TGF-β₁ – was downregulated by β-blocker treatment.

**Conclusions:** Our data support the concept that TGF-β₁ acts downstream of angiotensin II in cardiomyocytes, and furthermore, highlight the critical role of the β-adrenergic system in TGF-β₁-induced cardiac phenotype. Our data indicate for the first time, that TGF-β₁ directly influences mitochondrial energy metabolism by regulating UCP3 expression. β-blockers may act beneficially by normalizing regulatory mechanisms of cellular hypertrophy and energy metabolism.

Citation: Huntgeburth M, Tiemann K, Shahverdyan R, Schlüter KD, Schreckenberg R, et al. (2011) Transforming Growth Factor β₁ Oppositely Regulates the Hypertrophic and Contractile Response to β-Adrenergic Stimulation in the Heart. PLoS ONE 6(11): e26628. doi:10.1371/journal.pone.0026628

Editor: Shahab A. Akhter, University of Chicago, United States of America

Received April 16, 2011; Accepted September 29, 2011; Published November 17, 2011

Copyright: © 2011 Huntgeburth et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported in part by the Deutsche Forschungsgemeinschaft (RO1306/2-2 to SR and WHZ, HU1583/2-1 to MH, and SFB656 C3 to KT), the Center for Molecular Medicine Cologne (CMMC; project A6, to SR), the Köln Fortune Program of the Medical Faculty of the University of Cologne (to MH), and by a research grant from Boehringer-Ingelheim. MB is funded by the Deutsche Forschungsgemeinschaft (KFO 196). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: stephan.rosenkranz@uk-koeln.de

† These authors contributed equally to this work.

Introduction

Transforming growth factor-β₁ (TGF-β₁) is a 25-kDa homodimeric protein that is involved in numerous cellular processes [1,2]. In the heart, TGF-β₁ is expressed at high levels during embryonic development and pathology [3–6]. Both, TGF-β₁ ligand and its two serine-threonine kinase receptors, termed TGF-β receptor type I and II (TβRI and TβRII), are present in cardiac tissue, and...
all are expressed in cardiac myocytes and non-myocytes [4–6]. TGF-β1 has been implicated in a number of cardiac diseases such as pressure overload hypertrophy, post myocardial infarction ventricular remodeling, idiopathic hypertrophic cardiomyopathy, and dilative cardiomyopathy [5,6]. In particular, TGF-β1 is highly expressed in hypertrophic myocardium during the transition from stable hypertrophy to heart failure [7], indicating that it may play a role in the functional deterioration of the hypertrophied heart.

Ventricular remodeling is a dynamic process of alterations in size, shape and function of the left ventricle that involves adaptive and/or pathologic changes of cardiac myocytes and interstitial tissue. It is well established that activation of neuroendocrine mechanisms such as the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system as well as the induction of local mediators contribute to the structural and functional alterations in the hypertrophied heart [5–12]. TGF-β1 may be a crucial mediator of cardiac remodeling through direct and indirect actions in cardiomyocyte hypertrophy, fibroblast proliferation, and extracellular matrix metabolism [5,6]. While increased TGF-β1 levels were associated with cardiac hypertrophy and fibrosis [13,14], the loss of one TGF-β1 allele in heterozygous TGF-β1 deficient mice resulted in decreased fibrosis of the aging heart [15]. An extensive body of evidence suggests a direct functional association between TGF-β1, the RAAS, and the β-adrenergic system. Several studies have demonstrated that angiotensin II induces TGF-β1 mRNA and protein expression in cardiomyocytes and fibroblasts via the angiotensin type 1 (AT1) receptor in vitro [4–6], and appears to be required for angiotensin-induced cardiac hypertrophy in vivo [16]. In addition, TGF-β1 was shown to modulate the number and function of β-adrenergic receptors in various cell types [5,17], and to alter β-adrenergic signaling in the heart in vivo [13,18]. However, the precise interplay and the functional consequences of the network involving TGF-β1, the RAAS, and the β-adrenergic system have not been thoroughly characterized.

To better understand the mechanisms by which TGF-β1 induces cardiac fibrosis and hypertrophy, and furthermore may contribute to myocardial dysfunction, we took advantage of a transgenic mouse model that overexpresses a mature form of TGF-β1. Based on the well established connection between TGF-β1, the RAAS and the β-adrenergic system, TGF-β1 transgenic mice were chronically treated with a β-adrenergic receptor antagonist, or an antibody against the TGF-β1 receptor, in vivo [4–6], and appears to be required for the functional consequences of the network involving TGF-β1, the RAAS, and the β-adrenergic system have not been thoroughly characterized.

To better understand the mechanisms by which TGF-β1 induces cardiac fibrosis and hypertrophy, and furthermore may contribute to myocardial dysfunction, we took advantage of a transgenic mouse model that overexpresses a mature form of TGF-β1. Based on the well established connection between TGF-β1, the RAAS and the β-adrenergic system, TGF-β1 transgenic mice were chronically treated with a β-adrenergic receptor antagonist, or an antibody against the TGF-β1 receptor. The results identify TGF-β1 as an important regulator of cardiomyocyte hypertrophy and function. Furthermore, our data suggest that the β-adrenergic system is critically involved in TGF-β1-induced cardiac phenotype, as TGF-β1 promotes the hypertrophic responsiveness to β-adrenergic stimulation, whereas it impairs the contractile response to β-adrenergic stimuli by affecting the energy metabolism in the heart.

### Materials and Methods

#### Animals and treatment

Alb/TGF-β1(cys223ser) transgenic mice were generated and maintained as described [13,19]. The TGF-β1 cDNA encodes cysteine-to-serine substitutions at amino acid residues 223 and 225, resulting in preferential secretion of mature TGF-β1 [20]. Mice were treated from week 3 (immediately after weaning) to week 8 with either metoprolol (350 mg/kgBW/d) or telmisartan (10 mg/kgBW/d), each supplied with the drinking water, or by intraperitoneal application of soluble TGF-β1 receptor-Fc (sR-Fc; 1 mg/kgBW every other day). The latter compound was previously shown to act as a potent TGF-β antagonist [21]. All investigations were carried out at the age of 8 weeks, and all animal studies were performed according to NIH and Institutional animal care and use guidelines, and were approved by the local animal care authorities.

#### Human heart tissue

Left ventricular tissue was obtained from explanted hearts of patients with dilative cardiomyopathy (DCM) undergoing heart transplantation. Groups consisted of patients without beta-blocker treatment (DCM) and with beta-blocker (metoprolol) treatment. In DCM hearts, left ventricular ejection fraction (LVEF) was <40%. Non-failing controls represent healthy donor hearts that could not be implanted for whatever reason. The use of myocardial tissue samples was approved by the local ethics committee, and written informed consent was obtained from all patients.

#### Tissue homogenization, isolation of mitochondria and Western blot analyses

Left ventricular tissue was homogenized by incubation in extraction buffer (10 mM cacodylic acid, 150 mM NaCl, 1 μM ZnCl2, 20 mM CaCl2, 1.5 mM Na3VO4, 0.01% Triton-X100, pH 5.0) for 12 h at 4°C and subsequent centrifugation for 10 min at 1,200 × g. For isolation of mitochondria, fresh tissue was repeatedly minced in ice-cold STE, chopped in ice-cold STE buffer (250 mM sucrose, 5 mM Tris, 2 mM EGTA, pH 7.4 at 4°C) and rinsed. The chopped tissue was subjected to proteinase digest and disrupted in a Dounce homogenizer with a tight plunger. The homogenate was centrifuged at 700 × g for 10 minutes at 4°C, the supernatant was filtered through cheese cloth and centrifuged at 8,000 × g for 10 minutes. The pellet was resuspended in 40 μl of RIPA-buffer, subjected to sonication and the mitochondrial protein content was assayed using the bicinchoninic acid method (BioRad). Similar amounts of protein were resolved on a 10% SDS-polyacrylamide electrophoresis gel, and the proteins were transferred to Immobilon and subjected to Western blot analysis using antibodies that recognize TGF-β1 (R&D), RasGAP, UCP-3 (Affinity BioReagents), or cytochrome c oxidase complex IV (COX-I; Invitrogen).

#### Morphometric analysis of myocardial tissue

Fixation of myocardial tissue was performed by retrograde perfusion fixation as previously described [22]. Animals were perfused with either ice-cold NaCl 0.9% (immunohistochemistry) or 3% glutaraldehyde (morphometric and stereological analysis). Routine tissue stains were obtained from transversally cut hearts that were either fixed in 4% buffered formalin or snap-frozen in

### Table 1. Oligonucleotide sequences for primer and probe sets for rat cardiomyocytes.

| Primer/Probe | Sequence |
|-------------|----------|
| UCP2 forward primer | 5'-TCATCAAAGATATCTCTCCTGAAAGC-3' |
| UCP2 reverse primer | 5'-TGACGGTGGTGCAGACGA-3' |
| UCP2 probe | 5'-FAM-TGACAGACGACCTCCCGACT-TAMRA-3' |
| UCP3 forward primer | 5'-GTGACTTATGACTCATCAAGGA-3' |
| UCP3 reverse primer | 5'-GCTCCAAGGGCAGAACAAAG-3' |
| UCP3 probe | 5'-FAM-CTGACTCTTACCTGCTTACTGCA-3' |

[doi:10.1371/journal.pone.0026628.t001]
liquid nitrogen. After paraffin sections were embedded, they were stained with hematoxylin and eosin. Tissue sampling and section staining were performed according to the orientator method [23]. Fractional areas of cardiac myocytes, cardiac fibroblasts, and interstitium were measured on 12 differentially orientated semithin sections per animal using the point-counting method [22]. Myocyte diameters were measured on longitudinal sections with a semiautomatic image analyzing system and corrected for sarcomere length.

RNA isolation and quantitative real-time PCR

For UCP mRNA expression analyses, total RNA was isolated using the RNeasy Fibrous Tissue Mini Kit (Qiagen). cDNA was synthesized using the SuperScript III first-strand synthesis system with random hexamers (Invitrogen). For expression analyses of atrial natriuretic factor (ANF) and ornithine decarboxylase (ODC), mouse hearts were isolated and perfused in the Langendorff-mode. A subset was stimulated with isoprenaline (1 μM), and perfusion was prolonged for 2 hours. Release of lactate dehydrogenase was monitored to control for sarcolemmal integrity. Subsequently, ventricular tissue was dissected and RNA was extracted using RNA-Clean (AGS, Heidelberg, Germany). Total RNA from cultured cardiomyocytes was isolated using the TRizol method (Invitrogen). Reverse transcription was performed using Sensi-Script reverse transcriptase (Qiagen) and oligo-dt primers for ANF, ODC, and β-actin as described [13,18]. Quantitative real-time PCR was performed using TaqMan gene expression assays (Applied Biosystems) or SYBR Green Master Mix as indicated. Primers used are listed in table 1. Relative abundance of the gene of interest was calculated after normalization to 18S ribosomal RNA or β-actin as indicated.

Dobutamine stress echocardiography

Images were obtained by using a HDI-5000 ultrasound device (Philips Medical Systems, Bothell, WA, USA) equipped with a linear array transducer (15 MHz) as described [24]. At least 20 cardiac cycles were obtained for each view, and each imaging plane was acquired three times to assess reproducibility. Parasternal short-axis views were divided into six segments, and long axis views were divided into seven segments [25]. The endocardial borders were manually traced on the innermost endocardial edge while the epicardial borders were defined by tracing along the first bright pixel adjacent to myocardial tissue [26]. Left ventricular mass (LVM) and LVEF were assessed as previously described [24]. The resistive index (RI) was calculated as $1 - \frac{\text{enddiastolic velocity}}{\text{systolic velocity}}$. Dobutamine was administered intravenously at 10, 20, and 40 μg/kgBW/min after microsurgical cannulation of the tail vein. This procedure corresponds to the recommended protocol of the American Society of Echocardiography that is used in humans [27]. 2D- and M-mode registrations were recorded at each level of dobutamine.

Contractility of isolated cardiac myocytes

Cardiac myocytes were isolated by standard procedures as described [28]. Briefly, mouse hearts were exposed to collagenase digest in the Langendorff-mode, minced, and further digested by incubation with collagenase buffer. The suspension was filtered, and cardiomyocytes were separated from non-myocytes by centrifugation. Finally, physiological calcium concentrations were readjusted by step-wise increases to 1000 nmol/l, and plated on laminin-coated culture dishes. Cell contraction was investigated using a cell-edge detection system as previously described [29]. Briefly, cells were stimulated with biphasic electrical stimuli composed of two equal but opposite rectangular 50-V stimuli of 0.5 ms duration. Each cell was stimulated at 1, 0.5, and 2 Hz for 1 min. Every 15 s the next five contractions were averaged. The mean of these four measurements at a given frequency was used to

Figure 1. Characterization of myocardial tissue in wild type (WT) and TGF-β1 transgenic mice (TGF-β1) that have been treated with either metoprolol (METO), telmisartan (TELM), or soluble TGF-βR-Fc (sR-Fc). (A) Myocardial TGF-β1 protein expression as determined by Western blotting in heart homogenates from the various groups as indicated. RasGAP served as lysate control. (B) Body weight, heart weight, and heart/body weight ratio (n = 30–57 animals in each group). (C–F) Morphometric analysis of myocardial tissue (n = 5–9 animals in each group). Shown are the fractional areas of connective tissue (C), cardiac fibroblasts (D), cardiac myocytes (E), and cardiomyocyte diameter (F). *p<0.05 vs. WT, **p<0.05 vs. untreated TGF-β1 mice.
doi:10.1371/journal.pone.0026628.g001

Figure 2. Induction of (A) atrial natriuretic factor (ANF) and (B) ornithine decarboxylase (ODC) mRNA by isoprenaline in hearts from TGF-β1 transgenic mice (TGF-β1) that have been treated with either metoprolol (METO), telmisartan (TELM), or soluble TGF-βR-Fc (sR-Fc). Data are expressed as fold-increase relative to saline-perfused hearts. *p<0.05 vs. WT mice.
doi:10.1371/journal.pone.0026628.g002
define the contractility of a given cell. Cell lengths were measured at a rate of 500 Hz via a line camera.

Statistical analyses
All data are expressed as means ± SEM. Statistical significance was estimated by ANOVA, followed by post-hoc analysis (Student-Neuman-Keuls test), or by using the Student’s t-test for paired or unpaired observations, as appropriate. A p value of less than 0.05 was considered statistically significant.

Results
Cardiac hypertrophy in TGF-β1 transgenic mice is prevented by chronic β-adrenergic receptor blockade
Compared to wild-type mice, transgenic mice overexpressing a mature form (cys231,225-ser) of TGF-β1 (Fig. 1A) displayed cardiac hypertrophy, as indicated by an increase in heart weight (170.5 ± 3.4 vs. 122.3 ± 3.4 mg; p < 0.05) with no change in body weight, resulting in a significant increase of the heart-to-body-weight ratio (6.8 ± 0.1 vs. 5.1 ± 0.1 mg/g; p < 0.05; Fig. 1B). The data on cardiac hypertrophy in TGF-β1 transgenic mice have been published previously [13] and are included here for completeness. Cardiac hypertrophy was not due to hypertension as the invasively measured mean arterial blood pressure was similar in wild type and transgenic mice (99.7 ± 4.2 vs. 98.9 ± 4.3 mmHg, n = 7 in each group, n.s.). In order to investigate whether the TGF-β1-induced cardiac phenotype involved neuro-endocrine activation, TGF-β1 transgenic mice were chronically treated with the β-adrenergic blocker metoprolol, the angiotensin AT1 receptor antagonist telmisartan, or a TGF-β antagonist (sR-Fc). While neither treatment affected the elevated TGF-β1, whereas telmisartan did not (Fig. 3A and B). Under basal conditions, there was no difference in LVEF between wild-type and TGF-β1 mice (56.2 ± 3.6 vs. 61.8 ± 6.7%; n.s.), and none of the treatments had a significant effect on systolic function (Fig. 3C). Likewise, the resistive index (RI) as a measure of LV afterload was similar in all groups (Fig. 3D).

In order to investigate the influence of TGF-β1 overexpression and the various pharmacological interventions on the contractile response to β-adrenergic stimuli, we performed dobutamine stress echocardiography (DSE in vivo (Fig. 4A and B), and furthermore measured cell shortening of isolated cardiomyocytes in vitro. DSE revealed that the inotropic responsiveness to β-adrenergic stimulation was significantly diminished in TGF-β1 mice. At peak stress (dobutamine 40 μg/kg/min), the relative increase of LVEF was 16 ± 5% in TGF-β1 mice vs. 44 ± 5% in wild-type control mice (p < 0.01). Both metoprolol and sR-Fc completely restored the inotropic responsiveness to dobutamine (relative increase in LVEF 52 ± 10 and 43 ± 5%, respectively; both p < 0.05 vs. TGF-β1), whereas telmisartan had no significant effect (Fig. 4C).

To further extend these findings to isolated cells, cardiac myocytes were isolated from wild-type and TGF-β1 transgenic mice that had been treated with the various compounds. There was no difference in basal contractility between cells from wild-type and TGF-β1 mice. Consistent with the data obtained by DSE, the contractile response of isolated cardiac myocytes to β-adrenergic stimulation was diminished in TGF-β1 transgenic mice (Fig. 5A and B), and was restored by chronic treatment with either metoprolol or s-R-Fc, but not by telmisartan (Fig. 5C).

Mitochondrial uncoupling proteins are involved in the reduction of contractile reserve in TGF-β1 transgenic mice
Since our previous studies have demonstrated that hearts from TGF-β1 mice displayed an increased hypertrophic responsiveness to β-adrenergic stimulation and an increased contractility of atrial tissue when compared to wild-type mice [13], the fact that the contractile response in left ventricular tissue was diminished appeared surprising and warranted further investigation. To this end, we focused on mitochondrial uncoupling proteins (UCPs), which are involved in the regulation of energy metabolism in...
TGF-β and β-Adrenergic Responses in the Heart

A

![Graph showing the response to Dobutamine](image)

B

![Images showing echocardiograms](image)

C

![Bar charts showing ejection fraction](image)
mice. In contrast, the protein levels of UCP3 were significantly elevated in cardiac mitochondria that were isolated from TGF-ß1 transgenic mice as compared to wild-type animals (Fig. 6B). Thus, the ability of whole hearts and cardiac myocytes to adequately respond to ß-adrenergic stimuli (see Figures 4 and 5). Downregulation of myocardial UCPs by ß-adrenoceptor blockade occurred on the cellular level, as the induction of UCP2 and UCP3 by TGF-ß1 in isolated cardiomyocytes was abolished by pretreatment of the cells with metoprolol (not shown).

In order to assess whether UCPs are indeed involved with the reduced inotropic reserve in TGF-ß1 mice, we finally applied a pharmacological compound, genipin, which was previously shown to act as a potent UCP inhibitor [32]. When TGF-ß1 transgenic mice were injected with genipin (100 mg/kg i.p.), the contractile response to dobutamine during DSE was restored and comparable to the response of wild-type mice (Fig. 6C and D), and this correlated with the ability of whole hearts and cardiac myocytes to adequately respond to ß-adrenergic stimuli (see Figures 4 and 5). Downregulation of myocardial UCPs by ß-adrenoceptor blockade occurred on the cellular level, as the induction of UCP2 and UCP3 by TGF-ß1 in isolated cardiomyocytes was abolished by pretreatment of the cells with metoprolol (not shown).

Discussion

In this manuscript, we demonstrate that cardiac hypertrophy in mice overexpressing a mature form of TGF-ß1 is accompanied by the induction of hypertrophic responsiveness to ß-adrenergic stimulation, whereas the contractile ß-adrenergic response in LV was diminished. Further analyses revealed that TGF-ß1 impairs the inotropic reserve via regulation of myocardial UCPs which determine the efficiency of energy metabolism in cardiac myocytes. In fact, this is the first study to implement a role for TGF-ß1 in influencing mitochondrial energy metabolism in the heart. As expected, the inhibition of TGF-ß signaling by the use of sR-Fc prevented the cardiac phenotype of TGF-ß1 transgenic mice. Interestingly, chronic ß-adrenoceptor blockade was also able to reverse the morphological and functional changes of the heart, whereas blockade of the angiotensin AT1 receptor had no significant effect on the cardiac phenotype.

The applied model of transgenic mice overexpressing mature TGF-ß1 represents a situation of cardiac hypertrophy with preserved LV function at rest, but diminished contractile reserve. This scenario, which is manifested clinically as dyspnea on exertion in humans, is most likely to reflect the situation during the transition from compensated hypertrophy to overt heart failure. In this model, cardiac hypertrophy was not due to hypertension since there was no difference in systemic blood pressure between wild-type and TGF-ß1 transgenic mice. Instead, subcellular mechanisms were identified that provide a molecular explanation for the TGF-ß1-induced cardiac alterations. These include the induction of ODC, which is required for the hypertrophic responsiveness of the heart to ß-adrenergic stimulation [18], and the upregulation of myocardial UCPs, which impair the efficiency of the energy metabolism in muscle cells and thus are thought to contribute to the development of contractile dysfunction in heart failure [31,33]. UCPs are inner mitochondrial membrane proton transporters that dissipate the proton electrochemical gradient across the inner mitochondrial membrane, thereby reducing the energy force for ATP production during respiration [31].

The fact that AT1 receptor blockade was unable to prevent myocardial hypertrophy and dysfunction may appear surprising. However, the failure of telmisartan to impede the TGF-ß1-induced cardiac phenotype may actually be expected from previous studies. Schultz et al. provided direct proof that the hypertrophic cardiomyocyte growth induced by angiotensin II is mediated by TGF-ß1 in vivo [16]. In line with this study, it was shown by several experimental approaches that TGF-ß1 is required for angiotensin II-induced cardiomyocyte hypertrophy as it acts downstream of the AT1 receptor [reviewed in [5]]. Hence, in a model of TGF-ß1 overexpression, blockade of the AT1 receptor is not expected to prevent cardiac hypertrophy because its downstream effector is already upregulated. Therefore, our results are consistent with previous reports and further support the concept that TGF-ß1 acts as a downstream mediator of angiotensin II in cardiomyocyte hypertrophy and dysfunction.

While the morphological cardiac alterations that are induced by TGF-ß1 have been described in numerous studies [4–6], only little information is available on the functional consequences of increased TGF-ß1 activity in the heart. We have previously shown that overexpression of TGF-ß1 in transgenic mice was associated...
with an increase of myocardial β-adrenoceptor density and the downregulation of negative regulators such as G_{ia} and βARK-1, resulting in increased contractility of the atria in TGF-β₁ transgenic mice [13]. While the induction of a hypertrophic responsiveness to β-adrenergic stimulation and increased atrial contractility in TGF-β₁ transgenic mice appear as logical
Figure 6. A role for uncoupling proteins (UCPs) for the diminished contractile reserve in TGF-β1 transgenic mice. (A) Stimulation of rat cardiac myocytes with TGF-β1 (10 ng/ml) leads to upregulation of UCP2 and UCP3 mRNA (n = 4 in each group). (B) Western blot analysis of UCP3 expression in mitochondria isolated from myocardial tissue of WT and TGF-β1 mice. COX-I served as a loading control, and UCP3 knockout mice...
consequences of increased β-adrenergic signaling, it is difficult to understand why the inotropic response to β-adrenergic stimulation in LV is oppositely affected. The increased atrial contractility is likely due to a situation of diastolic LV dysfunction, where the left atrium has to compensate for the diminished LV filling in the hypertrophied heart (as reflected by the inverted E/A ratio in humans). Therefore, an impaired contractile reserve of the LV is frequently observed in diastolic heart failure. In contrast to ventricles, no significant influence of TGF-β1 on UCP2 and UCP3 gene expression was observed in atrial tissue (data not shown).

While TGF-β1 signaling has previously not been linked to cardiac energy metabolism, our data show that stimulation of isolated cardiac myocytes with TGF-β1 leads to an upregulation of UCP2 and UCP3 mRNA, and that overexpression of TGF-β1 in transgenic mice is associated with increased levels of UCP3 protein in cardiac mitochondria. A connection between TGF-β1 and UCPs was shown in other systems. For instance, TGF-β1 induces UCP expression in fetal rat brown adipocytes [34]. Recently, UCP2 was shown to be upregulated in an aortic regurgitation model of heart failure, and UCP3 upregulation and mitochondrial uncoupling were demonstrated in viable myocardium of chronically infarcted, failing rat hearts [35,36]. While these investigators did not relate their findings to TGF-β1, the upregulation of mitochondrial UCPs correlates with an increased expression of TGF-β1 in chronic myocardial infarction and heart failure that was shown in several animal studies as well as in human heart (reviewed in [5,6]).

The contractile function of the heart is dependent on a sufficient energy supply that has to be continuously adapted to the energy demand, provided by substrate utilization, oxidative phosphorylation, and ATP transfer and utilization [33]. Cardiac high-energy phosphate levels are reduced in heart failure, and they correlate with indexes of diastolic and systolic function, and with NYHA functional class and mortality in heart failure patients [33].

In our model, cardiac mitochondrial UCPs were upregulated albeit contractile function at rest was normal. The functional consequences of UCP upregulation only became evident when the isolated myocytes or mice were challenged with β-adrenergic receptor stimulators, and the inotropic reserve was assessed. Hence, the energy supply appeared adequate under resting conditions, but insufficient under high work-load conditions. This correlated with an upregulation of mitochondrial UCPs. Whether UCP upregulation is adaptive or maladaptive cannot be answered from our studies and requires further investigation. One speculate can, that UCPs may act as part of an adaptive response in the hypertrophied/failing heart, mainly by decreasing ROS production and lipotoxicity [36]. However, these potential benefits are likely to be offset by increased respiratory uncoupling. The resulting inefficiency of oxidative phosphorylation causes a decline in ATP transfer during high-energy phosphate metabolism. These metabolic abnormalities may contribute to contractile dysfunction and particularly to the loss of inotropic reserve that is characteristic of hypertrophied myocardium in (diastolic) heart failure [33]. Mitochondrial uncoupling might therefore play an important role in the progression from compensated hypertrophy to overt heart failure.

In addition to TGF-β1, the findings presented herein indicate that the β-adrenergic system is critically involved in the regulation of UCP expression. Consistent with this idea, β-adrenergic receptor agonists were shown to increase the expression levels of UCPs in L6 myotubes, adipose tissue, and the heart [37–39]. Likewise, some studies have indicated that the partial prevention of contractile LV dysfunction in animal models of heart failure by β-blockers such as bisoprolol was associated with an improvement of cardiac energy metabolism [40]. Here, chronic β-adrenergic receptor blockade by metoprolol restored the inotropic reserve in TGF-β1 transgenic mice, and this was accompanied by the downregulation of the initially upregulated myocardial UCPs. The functional relevance of UCPs in this context was demonstrated by the fact that genipin, acting as a UCP inhibitor [32], restored the inotropic responsiveness to β-adrenergic stimulation in isolated cardiomyocytes and in vivo. This may implicate that their upregulation is critically involved in the diminished contractile β-adrenergic response in TGF-β1 transgenic mice. Although the data obtained in human myocardium are based on a small number of samples.
and therefore have to be interpreted with caution, they indicate that the above mechanisms may be relevant in humans. As shown in Figure 7, myocardial UCP3 levels were elevated in hearts from DCM patients not receiving β-blocker treatment, while this was not the case in patients receiving metoprolol. These data are consistent with recent reports which indicate that energy deficiency in heart failure is associated with increased cardiac mitochondrial UCP expression and/or activity in humans. Murray et al. reported that UCP2 and UCP3 were upregulated in myocardial samples of patients with ischemia-associated cardiomyopathy [41]. Likewise, increased UCP activity was found in patients with obesity-related diabetic cardiomyopathy [42]. These data implicate that β-blockers may act beneficially in heart failure at least in part by augmenting cardiac energy efficiency.

Taken together, our data demonstrate that TGF-β1 oppositely regulates the hypertrophic and contractile response to β-adrenergic stimulation in the heart, leading to a phenotype of cardiac hypertrophy and myocardial dysfunction. The impairment of the inotropic reserve in TGF-β1 hearts from transgenic mice is linked to an upregulation of mitochondrial UCPS which influence cardiac energy metabolism. Furthermore, our findings highlight the critical role of the β-adrenergic system in TGF-β1-induced cardiac phenotype and indicate that β-blockers may act beneficially in cardiac hypertrophy and dysfunction at least in part by normalizing regulatory mechanisms of cellular hypertrophy and energy metabolism.

Acknowledgments

Alb/TGF-β1(cys223,225ser) transgenic mice were kindly provided by S.S. Thorgergsson and N. Sanderson (National Cancer Institute, NIH, Bethesda, MD/USA). The TGF-β antagonist a TGF-βR-Fc was kindly provided by Victor Koteliants (Biogen Inc., Cambridge, MA), and the RasGAP antibody was a kind gift from Andrius Kazlauskas (Harvard Medical School, Boston). This manuscript contains parts of a doctoral thesis by Robert Shaverdyan, who was supported by a doctoral scholarship from the Köln Fortune Program, Medical Faculty of the University of Cologne.

Author Contributions

Conceived and designed the experiments: SR MB KT M-LG K-DS WHZ.
Performed the experiments: MH RS M-LG SM RS EC AG SR KT.
Analyzed the data: SR MH RS M-LG MG AG KT MB WHZ.
Contributed reagents/materials/analysis tools: JME. Wrote the paper: MH TK SR.

References

1. Massagué J. Blain SW, Le RS (2000) TGF-β signaling in growth control, cancer, and heritable disorders. Cell 103: 295–309.
2. Shi Y, Massagué J (2003) Mechanisms of TGF-β signaling from the cell membrane to the nucleus. Cell 113: 683–700.
3. Millan FA, Denhez F, Koudaia P, Akhurst RJ (1991) Embryonic gene expression patterns of TGF β 1, beta 2, and beta 3 suggest different developmentnal functions in vivo. Development 111: 131–143.
4. Brand T, Schneider MD (1995) The TGF-β superfamily in myocardium: Ligands, receptors, transduction, and function. J Mol Cell Cardiol 27: 3–18.
5. Rosenkrann S, Flesch M, Amann K, Haeuseler C, KIIter H, et al. (2002) Decreased growth factor heterozygous mice. J Mol Cell Cardiol 32: 187–195.
6. To¨rnig J, Amann K, Ritz E, Nichols C, Zeier M, et al. (1996) Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure: the effects of ramipril, nifedipine, and metoxypidine. Am J Physiol 270: H67–H75.
7. Mattfeldt T, Mall G, Gharebaghi H, Møller P (1990) Estimation of surface area and length with the orientor. J Microsc 159: 301–317.
8. Tzannes MC, Derijcke D, Slack L, Amin N, Lewalter T, et al. (2003) Increased myocardial contraction and blood pressure in C57BL/6 mice during early postnatal development. Am J Physiol Heart Circ Physiol 284: H1954–H1962.
9. Nakajima H, Nakajima HO, Salcher O, Dittie AS, Dembowsky K, et al. (2000) Alterations of myocardial UCP expression and/or activity in humans. Circ Res 86: 571–579.
10. Cohn JN, Ferrari R, Sharpe N (2000) Cardiac remodeling concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an international forum on cardiac remodeling. J Am Coll Cardiol 35: 569–582.
11. Yamazaki T, Komuro I, Yazaki I (1999) Role of the renin angiotensin system in myocardial infarction and cardiac remodeling. Cardiovasc Res 45: 410–417.
12. Bo¨hm M, Frangeogianis NG (2007) The role of TGF-β signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res 74: 184–195.
13. Bobey MO, O’Neill L, Meredith AL, Bung OHL, Brooks WW, Conrad, et al. (1994) Alterations in cardiac gene expression during the transition from stable hypertrophy to failure. Circ Res 75: 23–32.
14. Cohn JN, Ferrari R, Sharpe N (2000) Cardiac remodeling concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an international forum on cardiac remodeling. J Am Coll Cardiol 35: 569–582.
15. Engelhardt S, Heim I, Wieismann F, Lohse MJ (1999) Progressive hypertrophy and heart failure in beta 1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 96: 7059–7064.
16. Böhm M, Kouchi I, Schnabel P, Zolk O (1999) Transition from hypertrophy to failure: β-adrenergic desensitization of the heart. Heart Failure Rev 4: 329–351.
17. Rosenkranz S, Flesch M, Amann K, Haeuseler C, KIIter H, et al. (2002) Altersations of β-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-β1. Am J Physiol Heart Circ Physiol 283: H1253–H1262.
18. Nakajima H, Nakajima HO, Suhert O, Dittie AS, Dembowsky K, et al. (2000) Atrial but not ventricular fibrosis in mice expressing a mutant transforming growth factor β transgene in the heart. Circ Res 86: 571–579.
19. Brooks WW, Conrad CH (2000) Myocardial fibrosis in transforming growth factor heterozygous mice. J Mol Cell Cardiol 32: 187–195.
20. Samuel SK, Hurta RA, Kondaiah P, Khalil N, Turley EA, et al. (1992) Autocrine induction of tumor protease production and invasion by metallothio-ne-regulated TGF-beta 1 (Ser 223, 225). EMBO J 11: 1599–1605.
21. Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, et al. (2001) Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor β1. J Exp Med 194: 809–821.
22. Tornig J, Amann K, Ritz E, Nichols C, Zeier M, et al. (1996) Concentrations that allow normal growth factor β1 expression in its transgenic mice were kindly provided by S.S. Thorgergsson and N. Sanderson (National Cancer Institute, NIH, Bethesda, MD/USA). The TGF-β antagonist a TGF-βR-Fc was kindly provided by Victor Koteliants (Biogen Inc., Cambridge, MA), and the RasGAP antibody was a kind gift from Andrius Kazlauskas (Harvard Medical School, Boston). This manuscript contains parts of a doctoral thesis by Robert Shaverdyan, who was supported by a doctoral scholarship from the Köln Fortune Program, Medical Faculty of the University of Cologne.
37. Nagase I, Yoshida T, Saito M (2001) Up-regulation of uncoupling proteins by β-adrenergic stimulation in L6 myotubes. FEBS Lett 494: 173–180.

38. Ramsey TG, Richards MP (2007) β-adrenergic regulation of uncoupling protein expression in swine. Comp Biochem Physiol A Mol Integr Physiol 147: 395–403.

39. Ishizawa M, Mizushige K, Noma T, Guo P, Murakami K, et al. (2006) An antioxidant treatment potentially protects myocardial energy metabolism by regulating uncoupling protein 2 expression in a chronic β-adrenergic stimulation rat model. Life Sci 78: 2974–2982.

40. Hugel S, Horn M, De Groot M, Remkes H, Dienesch C, et al. (1992) Effects of ACE inhibition and β-receptor blockade on energy metabolism in rats postmyocardial infarction. Am J Physiol (Heart Circ Physiol). H2167–H2175.

41. Murray AJ, Anderson SE, Watson GC, Radda GK, Clarke K (2004) Uncoupling proteins in human heart. Lancet 364: 1706–1708.

42. Boudina S, Sena S, Throhsald H, Sheng X, Wright JJ, et al. (2007) Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes 56: 2457–2466.